Vice President, Development Data Science

Why Join Us? Parabilis Medicines is a clinical‑stage biopharmaceutical company that leverages its proprietary peptide platform to develop novel treatments for diseases with urgent unmet needs, including a new class of stabilized, cell‑penetrant alpha‑helical peptides – Helicons™ – that modulate intracellular proteins. With a focused pipeline of first‑in‑class therapies in oncology and a $305 million Series F financing, Parabilis is positioned for significant growth.

• Lead the Clinical Data Science function and oversee end‑to‑end strategy for Real‑World Data (RWD) / Real‑World Evidence (RWE) and clinical analytics to inform trial design, biomarker development, and site selection.
• Partner with Clinical Development, Operations, Biostatistics, Translational biology, Regulatory, and the broader Data Science & Engineering teams to maximize program success.
• Develop and own the Clinical Data Science strategy, representing the team in cross‑functional governance and portfolio forums.
• Design and oversee RWE studies – including synthetic/external control arms, patient matching, and trial emulation – to contextualize clinical trial results.
• Use RWD to inform eligibility criteria, endpoints, enrichment strategies, dose/regimen selection, and go/no‑go decisions.
• Integrate RWD with internal clinical, biomarker, and translational data to support forward and reverse translation, target and indication strategy, and resistance mechanism analyses.
• Identify, evaluate, and prioritize RWD sources (EHR, claims, registries, genomic/omic datasets, imaging, PROs) and lead collaborations with data providers and academic/industry partners.
• Partner with Engineering and Data Science to define secure, scalable, compliant RWD infrastructure and analytic environments, ensuring data quality and governance for regulatory‑grade analyses.
• Build and lead a high‑performing Clinical Data Science team, providing clear objectives, feedback, and growth opportunities.
• Communicate complex methodologies and results to clinical, technical, and executive stakeholders, and support regulatory and payer interactions where RWE drives decision‑making.
• Ensure all RWD/RWE activities meet regulatory, ethical, and privacy standards, implement reproducibility and quality documentation, and adapt internal practices to evolving external expectations.

• PhD, MD, Pharm
  
  D, or MS in Epidemiology, Biostatistics, HEOR, Data Science, or a related quantitative field.
• 12–15+ years of experience in pharma/biotech, healthcare technology, or related sectors, with a significant focus on RWD/RWE and clinical development; oncology experience strongly preferred.
• Proven track record designing and delivering impactful RWE studies to inform clinical, regulatory, or payer decisions.
• Strong understanding of clinical trial design, biostatistics fundamentals, and translational/biomarker concepts, ideally in oncology or immuno‑oncology.
• Demonstrated experience building, leading, and developing high‑performing quantitative teams in a matrixed environment.
• Hands‑on familiarity with major RWD types (EHR, claims, registries, genomic/omic datasets) and key vendors/platforms.
• Proficiency with modern analytic tools and programming environments (R, Python, SQL) and the ability to guide the development of robust, reproducible analytic workflows.
• Excellent communication and influencing skills, with the ability to engage clinicians, statisticians, senior leaders, and external partners.

The base salary range is $325,000–$380,000 per year, depending on experience, qualifications, and internal practices. The total compensation package also includes an annual target bonus, equity, and a comprehensive suite of competitive benefits.

Parabilis Medicines is an equal‑opportunity employer. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.